Vascular Targeted Photodynamic Therapy with Padeliporfin for Low Risk Prostate Cancer Treatment: Midterm Oncologic Outcomes.
We assessed the midterm oncologic outcomes of vascular targeted photodynamic therapy with padeliporfin for low risk prostate cancer treatment.



We prospectively assessed all patients treated with vascular targeted photodynamic therapy for low risk prostate cancer at our center. Patients were followed every 6 months. All patients underwent prostate biopsies 6 months after treatment or when there was biological or clinical progression. The primary end point was progression-free survival. Secondary end points were absent clinically significant cancer in the treated lobes, radical therapy and the prostate specific antigen rate. Variables were compared with the chi-square, Mann-Whitney or Wilcoxon test. Progression-free survival is reported with Kaplan-Meier curves.



A total of 82 men were treated with vascular targeted photodynamic therapy. Median followup was 68 months (range 6 to 89). Median progression-free survival was 86 months (95% CI 82-90). Median prostate specific antigen decreased significantly by 41% 6 months after treatment and it remained stable during followup (p <0.001). A total of 115 lobes were treated and absent clinically significant cancer was achieved in 94 (82%). Of the 82 patients 20 (24%) underwent radical therapy, including radical prostatectomy in 18 and brachytherapy in 2, at a median of 22 months (range 6 to 86). Study limitations include a single arm design, small population size and midterm followup.



Padeliporfin vascular targeted photodynamic therapy for low risk prostate cancer achieved an 82% rate of absent clinically significant cancer in treated lobes and 76% of patients avoided radical therapy at a median followup of 68 months. However, longer followup is required to determine long-term outcomes.
Urology Department, University Hospital of Angers, Angers, France. Electronic address: souhil.lebdai@gmail.com.
Souhil
S
Lebdai
Urology Department, University Hospital of Angers, Angers, France.
Pierre
P
Bigot
Urology Department, University Hospital of Angers, Angers, France.
Pierre-Adrien
PA
Leroux
Urology Department, University Hospital of Angers, Angers, France.
Louis-Paul
LP
Berthelot
Urology Department, University Hospital of Angers, Angers, France.
Pierre
P
Maulaz
Urology Department, University Hospital of Angers, Angers, France.
Abdel-Rahmene
AR
Azzouzi
D000368:Aged; D001429:Bacteriochlorophylls / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D000077982:Progression-Free Survival; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D015996:Survival Rate; D016896:Treatment Outcome
D001429:Bacteriochlorophylls; D017430:Prostate-Specific Antigen; C503696:padeliporfin
WST11 compound; photochemotherapy; prostatic neoplasms; therapeutic occlusion; treatment outcome